Autolus Therapeutics (AUTL)
(Delayed Data from NSDQ)
$3.73 USD
-0.12 (-3.12%)
Updated Sep 20, 2024 04:00 PM ET
After-Market: $3.72 -0.01 (-0.27%) 7:58 PM ET
3-Hold of 5 3
F Value D Growth B Momentum F VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$3.73 USD
-0.12 (-3.12%)
Updated Sep 20, 2024 04:00 PM ET
After-Market: $3.72 -0.01 (-0.27%) 7:58 PM ET
3-Hold of 5 3
F Value D Growth B Momentum F VGM
Zacks News
Are Medical Stocks Lagging Ascendis Pharma (ASND) This Year?
by Zacks Equity Research
Here is how Ascendis Pharma A/S (ASND) and Autolus Therapeutics PLC Sponsored ADR (AUTL) have performed compared to their sector so far this year.
Strength Seen in Autolus Therapeutics PLC Sponsored ADR (AUTL): Can Its 6.3% Jump Turn into More Strength?
by Zacks Equity Research
Autolus Therapeutics PLC Sponsored ADR (AUTL) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
2seventy bio, Inc. (TSVT) Surges 28.2%: Is This an Indication of Further Gains?
by Zacks Equity Research
2seventy bio, Inc. (TSVT) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
Autolus (AUTL) Selects Cardinal Health for Cell Therapy Supply
by Zacks Equity Research
Autolus (AUTL) partners with Cardinal Health to bring next-generation CAR-T cell therapies to the market and revolutionize cancer treatment.
Has Acasti Pharma (ACST) Outpaced Other Medical Stocks This Year?
by Zacks Equity Research
Here is how Acasti Pharma (ACST) and Autolus Therapeutics PLC Sponsored ADR (AUTL) have performed compared to their sector so far this year.
Is Alaunos Therapeutics (TCRT) Outperforming Other Medical Stocks This Year?
by Zacks Equity Research
Here is how Alaunos (TCRT) and Autolus Therapeutics PLC Sponsored ADR (AUTL) have performed compared to their sector so far this year.
Autolus Therapeutics PLC Sponsored ADR (AUTL) Loses 22.1% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
by Zacks Equity Research
The heavy selling pressure might have exhausted for Autolus Therapeutics PLC Sponsored ADR (AUTL) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.
Autolus Therapeutics PLC Sponsored ADR (AUTL) Moves 35.5% Higher: Will This Strength Last?
by Zacks Equity Research
Autolus Therapeutics PLC Sponsored ADR (AUTL) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions could translate into further price increase in the near term.
Autolus Therapeutics PLC Sponsored ADR (AUTL) Surges 6.5%: Is This an Indication of Further Gains?
by Zacks Equity Research
Autolus Therapeutics PLC Sponsored ADR (AUTL) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
Autolus Therapeutics PLC Sponsored ADR (AUTL) Upgraded to Buy: What Does It Mean for the Stock?
by Zacks Equity Research
Autolus Therapeutics PLC Sponsored ADR (AUTL) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Moving Average Crossover Alert: Autolus Therapeutics
by Zacks Equity Research
Autolus Therapeutics plc (AUTL) is looking like an interesting pick from a technical perspective, as the company is seeing favorable trends on the moving average crossover front.
Is Autolus Therapeutics PLC Sponsored (AUTL) Stock Outpacing Its Medical Peers This Year?
by Zacks Equity Research
Is (AUTL) Outperforming Other Medical Stocks This Year?
Autolus Therapeutics' Shares March Higher, Can It Continue?
by Zacks Equity Research
As of late, it has definitely been a great time to be an investor in Autolus Therapeutics.
Is Autolus Therapeutics (AUTL) Stock a Solid Choice Right Now?
by Zacks Equity Research
Autolus Therapeutics (AUTL) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.
Autolus Therapeutics PLC Sponsored ADR (AUTL) Upgraded to Strong Buy: What Does It Mean for the Stock?
by Zacks Equity Research
Autolus Therapeutics PLC Sponsored ADR (AUTL) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Will Autolus Therapeutics Continue to Surge Higher?
by Zacks Equity Research
As of late, it has definitely been a great time to be an investor Autolus Therapeutics
5 Beaten-Down Biotech Stocks Set to Rebound in 2020
by Kinjel Shah
Here we discuss some biotech stocks, which are down this year so far but have the potential to bounce back next year.
Will Autolus Continue to Surge Higher?
by Zacks Equity Research
As of late, it has definitely been a great time to be an investor in Autolus Therapeutics.
Autolus Therapeutics (AUTL) in Focus: Stock Moves 8.5% Higher
by Zacks Equity Research
Autolus Therapeutics (AUTL) saw a big move last session, as its shares jumped more than 8% on the day, amid huge volumes.
Autolus Therapeutics (AUTL) Catches Eye: Stock Jumps 5.6%
by Zacks Equity Research
Autolus Therapeutics (AUTL) saw a big move last session, as its shares jumped nearly 6% on the day, amid huge volumes.
Alexandria Fully Leases New Built-to-Suit Facility to Autolus
by Zacks Equity Research
Alexandria Real Estate Equities' (ARE) new build-to-suit project in Rockville will serve as the U.S. headquarters and a commercial scale manufacturing site for Autolus.